{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T21:33:14Z","timestamp":1792359194128,"version":"4.4.0"},"reference-count":72,"publisher":"Media Sphere Publishing House","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["S.S. Korsakov J. Neuro. Psych."],"published-print":{"date-parts":[[2025,5,27]]},"abstract":"<jats:p>Objective. To determine, evaluate, and analyze the diagnostic value of various laboratory biomarkers of Alzheimer\u2019s disease (AD) in blood and cerebrospinal fluid (CSF). Material and methods. The concentrations of 93 potential biomarkers in plasma and CSF were studied in patients with AD at various stages (n=53) and independently in the group at the predementia stage (n=15). Results. Statistically significant correlations of various directions (p\u22640.05) were found between the coefficients characterizing the amyloidosis and neurodegeneration (A\u03b2-42\/A\u03b2-40, phTau181\/A\u03b2-42, phTau181\/oTau, oTau\/A\u03b2-42) with markers associated with neuroinflammation, vascular disorders, angiogenesis, neuroimaging changes, and neuropsychological indicators. Previous studies of markers associated with inflammation in CSF in AD patients have shown mixed results, and no markers have been introduced into clinical practice so far. Many biomarkers associated with two classical pathogenetic links and other pathophysiological processes have been identified. Conclusion. Coefficients reflecting two main pathogenetic processes in CSF of AD patients (A\u03b2-42\/A\u03b2-40, phTau181\/A\u03b2-42, phTau181\/oTau, oTau\/A\u03b2-42) are the most informative for verifying two main links in the disease pathogenesis\u2014amyloidogenesis and neurodegeneration. In the group of patients with amnestic mild cognitive impairment (aMCI), statistically significant relationships of cytokines associated with neuroinflammation, growth factors, and complement system protein with coefficients of amyloidosis and neurodegeneration in CSF, as well as PET, MRI, and neuropsychological tests were shown; therefore, these indicators can also be considered as potential diagnostic biomarkers of early stages and possible predictors of MCI conversion to dementia. Such markers as GFAP, apolipoprotein A1, GDF-15, IFN-\u03b3, IL-5, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17, VEGF, and complement C3 should be considered as objects for further research as biomarkers for early diagnosis.<\/jats:p>","DOI":"10.17116\/jnevro202512504243","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T05:14:52Z","timestamp":1748322892000},"page":"43","source":"Crossref","is-referenced-by-count":1,"special_numbering":"Vyp. 2","title":["A comprehensive study of Alzheimer\u2019s disease biomarkers in plasma and cerebrospinal fluid"],"prefix":"10.17116","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1190-0886","authenticated-orcid":false,"given":"A.K.","family":"Minochkin","sequence":"first","affiliation":[{"name":"Saint Petersburg City Hospital No. 40","place":["St. Petersburg, Russia"]},{"name":"Saint Petersburg State University","place":["St. Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3109-8795","authenticated-orcid":false,"given":"V.Yu.","family":"Lobzin","sequence":"additional","affiliation":[{"name":"Saint Petersburg State University","place":["St. Petersburg, Russia"]},{"name":"S.M. Kirov Military Medical Academy","place":["St. Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4723-802X","authenticated-orcid":false,"given":"A.Yu.","family":"Emelin","sequence":"additional","affiliation":[{"name":"Saint Petersburg State University","place":["St. Petersburg, Russia"]},{"name":"S.M. Kirov Military Medical Academy","place":["St. Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1223-0255","authenticated-orcid":false,"given":"Yu.P.","family":"Kopteva","sequence":"additional","affiliation":[{"name":"Saint Petersburg City Hospital No. 40","place":["St. Petersburg, Russia"]},{"name":"Saint Petersburg State University","place":["St. Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2686-8786","authenticated-orcid":false,"given":"O.A.","family":"Klitsenko","sequence":"additional","affiliation":[{"name":"Saint Petersburg City Hospital No. 40","place":["St. Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-4185","authenticated-orcid":false,"given":"S.V.","family":"Apalko","sequence":"additional","affiliation":[{"name":"Saint Petersburg City Hospital No. 40","place":["St. Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5036-1259","authenticated-orcid":false,"given":"S.G.","family":"Sherbak","sequence":"additional","affiliation":[{"name":"Saint Petersburg City Hospital No. 40","place":["St. Petersburg, Russia"]},{"name":"Saint Petersburg State University","place":["St. Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6743","reference":[{"key":"key-10.17116\/jnevro202512504243-1","unstructured":"Alzheimer Europe. Dementia in Europe Yearbook 2019: estimating the prevalence of dementia in Europe. 2020. Accessed Jan 24,2021.  https:\/\/www.alzheimereurope.org\/content\/download\/195515\/1457520\/file\/FINAL%20 05707%20Alzheimer%20Europe%20yearbook%202019.pdf"},{"key":"key-10.17116\/jnevro202512504243-2","unstructured":"The epidemiology and impact of dementia: current state and future trends. Geneva: World Health Organization. 2015"},{"key":"key-10.17116\/jnevro202512504243-3","unstructured":"Dementia. World Health Organization. Accessed: 5 September 2018. Available:  https:\/\/www.who.int\/mediacentre\/factsheets\/fs362\/en\/"},{"key":"key-10.17116\/jnevro202512504243-4","unstructured":"World Health Organization. Dementia: number of people affected to triple in next 30 years. 2017. Accessed: 5 September 2018. Available:  https:\/\/www.who.int\/mediacentre\/news\/releases\/2017\/dementia-triple-affected\/en\/"},{"key":"key-10.17116\/jnevro202512504243-5","doi-asserted-by":"publisher","DOI":"10.14412\/2074-2711-2022-2-35-42"},{"key":"key-10.17116\/jnevro202512504243-6","doi-asserted-by":"publisher","DOI":"10.30629\/2658-7947-2019-24-5-32-37"},{"key":"key-10.17116\/jnevro202512504243-7","doi-asserted-by":"publisher","DOI":"10.3233\/jad-179932"},{"key":"key-10.17116\/jnevro202512504243-8","unstructured":"FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD): Food and Drug Administration (US); Bethesda (MD): National Institutes of Health (US); 2016. Accessed 22.09.2017. Available from:  www.ncbi.nlm.nih.gov\/books\/NBK326791\/"},{"key":"key-10.17116\/jnevro202512504243-9","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro20171176233-40"},{"key":"key-10.17116\/jnevro202512504243-10","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-018-3507-y"},{"key":"key-10.17116\/jnevro202512504243-11","doi-asserted-by":"crossref","unstructured":"Auriacombe S, Helmer C, Amieva H, et al. Validity of the free and cued selective reminding test in predicting dementia: the 3C study. Neurology. 2010;74(22):1760-1767","DOI":"10.1212\/WNL.0b013e3181df0959"},{"key":"key-10.17116\/jnevro202512504243-12","doi-asserted-by":"crossref","unstructured":"Sarazin M, Berr C, de Rotrou J, et al. Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology. 2007;69(19):1859-1867","DOI":"10.1212\/01.wnl.0000279336.36610.f7"},{"key":"key-10.17116\/jnevro202512504243-13","doi-asserted-by":"crossref","unstructured":"Anand BG, Wu Q, Karthivashan G, et al. Amnestic syndrome. Amnestic syndrome Bioact. Mater. 2021;6(12):4491-4505","DOI":"10.1016\/j.bioactmat.2021.04.029"},{"key":"key-10.17116\/jnevro202512504243-14","doi-asserted-by":"crossref","unstructured":"Blennow K, Hampel H, Weiner M, et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131-144","DOI":"10.1038\/nrneurol.2010.4"},{"key":"key-10.17116\/jnevro202512504243-15","unstructured":"GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7:e105-25"},{"key":"key-10.17116\/jnevro202512504243-16","unstructured":"Lobzin VYu, Emelin AYu, Alekseeva LA. Cerebrospinal fluid biomarkers of neurodegeneration in the early diagnosis of cognitive disorders. Bulletin of the Russian Military Medical Academy. 2013;4(44):56-59. (In Russ.)"},{"key":"key-10.17116\/jnevro202512504243-17","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11020215"},{"key":"key-10.17116\/jnevro202512504243-18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-54204-z"},{"key":"key-10.17116\/jnevro202512504243-19","doi-asserted-by":"crossref","unstructured":"Buchhave P, Lennart M, Zetterberg H, et al. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012;69:98-106","DOI":"10.1001\/archgenpsychiatry.2011.155"},{"key":"key-10.17116\/jnevro202512504243-20","doi-asserted-by":"crossref","unstructured":"Hertze J, Lennart M, Zetterberg H, et al. Evaluation of CSF biomarkers as predictors of Alzheimer\u2019s disease: a clinical follow-up study of 4.7 years. J Alzheimers Dis. 2010;21:1119-1128","DOI":"10.3233\/JAD-2010-100207"},{"key":"key-10.17116\/jnevro202512504243-21","doi-asserted-by":"crossref","unstructured":"Ferreira D, Rivero-Santana A, Perestelo-P\u00e9rezet L. Improving CSF biomarkers\u2019 performance for predicting progression from mild cognitive impairment to Alzheimer\u2019s disease by considering different confounding factors: a meta-analysis. Front Aging Neurosci. 2014;6:287","DOI":"10.3389\/fnagi.2014.00287"},{"key":"key-10.17116\/jnevro202512504243-22","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911170"},{"key":"key-10.17116\/jnevro202512504243-23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.004"},{"key":"key-10.17116\/jnevro202512504243-24","doi-asserted-by":"crossref","unstructured":"Hansson O, Lehmann S, Otto M, et al. Advantages and disadvantages of the use of the CSF Amyloid beta (Abeta) 42\/40 ratio in the diagnosis of Alzheimer\u2019s Disease. Alzheimers Res Ther. 2019;11:34","DOI":"10.1186\/s13195-019-0485-0"},{"key":"key-10.17116\/jnevro202512504243-25","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-00967-z"},{"key":"key-10.17116\/jnevro202512504243-26","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-013-2957-0"},{"key":"key-10.17116\/jnevro202512504243-27","doi-asserted-by":"crossref","unstructured":"Yakhno NN, Koberskaya NN, Perepelov VA, et al. Magnetic resonance morphometry of the hippocampus and neuropsychological parameters in patients with Alzheimer\u2019s disease. Neurology, Neuropsychiatry, Psychosomatics. 2019;11(4):28-32. (In Russ.)","DOI":"10.14412\/2074-2711-2019-4-28-32"},{"key":"key-10.17116\/jnevro202512504243-28","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2009.139"},{"key":"key-10.17116\/jnevro202512504243-29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.003"},{"key":"key-10.17116\/jnevro202512504243-30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.008"},{"key":"key-10.17116\/jnevro202512504243-31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.005"},{"key":"key-10.17116\/jnevro202512504243-32","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"key-10.17116\/jnevro202512504243-33","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.55.11.1621"},{"key":"key-10.17116\/jnevro202512504243-34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.53221.x"},{"key":"key-10.17116\/jnevro202512504243-35","doi-asserted-by":"publisher","DOI":"10.1177\/1073191115602552"},{"key":"key-10.17116\/jnevro202512504243-36","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadm.2017.11.005"},{"key":"key-10.17116\/jnevro202512504243-37","unstructured":"Dubois B, Touchon J, Portet F, et al. Les cinq mots, \u00e9preuves simple et sensible pour le diagnostic de la maladie d\u2019Alzheimer. Presse Med. 2002;31(36):1696-1699"},{"key":"key-10.17116\/jnevro202512504243-38","doi-asserted-by":"crossref","unstructured":"Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer\u2019s disease. Am J Psychiatry. 1984;141:1356-1364","DOI":"10.1176\/ajp.141.11.1356"},{"key":"key-10.17116\/jnevro202512504243-39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1989.tb02233.x"},{"key":"key-10.17116\/jnevro202512504243-40","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.140.6.566"},{"key":"key-10.17116\/jnevro202512504243-41","unstructured":"Lobzin VYu. Vascular neurodegenerative cognitive disorders (pathogenesis, clinical manifestations, early and differential diagnosis). Diss. ... Doctor of Medical Sciences. St-Petersburg. 2016;333"},{"key":"key-10.17116\/jnevro202512504243-42","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9050524"},{"key":"key-10.17116\/jnevro202512504243-43","doi-asserted-by":"crossref","unstructured":"Qin T, Prins S, Groeneveld GJ, et al. Utility of Animal Models to Understand Human Alzheimer\u2019s Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals. Int J Mol Sci. 2020;21:3158","DOI":"10.3390\/ijms21093158"},{"key":"key-10.17116\/jnevro202512504243-44","doi-asserted-by":"crossref","unstructured":"Frost GR, Li YM. The role of astrocytes in amyloid production and Alzheimer\u2019s disease. Open Biol. 2017;7:170228","DOI":"10.1098\/rsob.170228"},{"key":"key-10.17116\/jnevro202512504243-45","doi-asserted-by":"crossref","unstructured":"Chmielewska N, Szyndler J, Makowska K, et al. Looking for novel, brain-derived, peripheral biomarkers of neurological disorders. Neurol Neurochir Pol. 2018;52:318-325","DOI":"10.1016\/j.pjnns.2018.02.002"},{"key":"key-10.17116\/jnevro202512504243-46","doi-asserted-by":"publisher","DOI":"10.3390\/cells12091309"},{"key":"key-10.17116\/jnevro202512504243-47","doi-asserted-by":"crossref","unstructured":"Zimetti F, Adorni MP, Marsillach J, et al. Connection between the altered HDL antioxidant and anti-inflammatory properties and the risk to develop Alzheimer\u2019s disease: a narrative review. Oxid Med Cell Long. 2021;7(2):16-21","DOI":"10.1155\/2021\/6695796"},{"key":"key-10.17116\/jnevro202512504243-48","doi-asserted-by":"crossref","unstructured":"Slot R, Van Harten AC, Kester MI, et al. Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer\u2019s Disease in Non-Demented Elderly. J Alzheimers Dis. 2017;56(2):687-697","DOI":"10.3233\/JAD-151068"},{"key":"key-10.17116\/jnevro202512504243-49","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-022-01721-1"},{"key":"key-10.17116\/jnevro202512504243-50","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2018.00008"},{"key":"key-10.17116\/jnevro202512504243-51","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413647"},{"key":"key-10.17116\/jnevro202512504243-52","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02565-0"},{"key":"key-10.17116\/jnevro202512504243-53","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13734"},{"key":"key-10.17116\/jnevro202512504243-54","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.700371"},{"key":"key-10.17116\/jnevro202512504243-55","doi-asserted-by":"publisher","DOI":"10.1590\/1980-5764-DN-2023-0027"},{"key":"key-10.17116\/jnevro202512504243-56","unstructured":"Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. Philadelphia, PA: Elsevier; 2017. 9th ed"},{"key":"key-10.17116\/jnevro202512504243-57","unstructured":"Artemov MV, Stanzhevsky AA. The use of magnetic resonance morphometry and positron emission tomography in the diagnosis of alzheimer\u2019s disease. Visualization in Medicine. 2021;2(3):22-27. (In Russ.)"},{"key":"key-10.17116\/jnevro202512504243-58","doi-asserted-by":"crossref","unstructured":"Sogawa K, Kodera Y, Satoh M, et al. Increased Serum Levels of Pigment Epithelium-Derived Factor by Excessive Alcohol Consumption-Detection and Identification by a Three-Step Serum Proteome Analysis. Alcohol Clin Exp Res. 2010;35:211-217","DOI":"10.1111\/j.1530-0277.2010.01336.x"},{"key":"key-10.17116\/jnevro202512504243-59","doi-asserted-by":"crossref","unstructured":"Lang V, Zille M, Infante-Duarte C, et al. Alzheimer\u2019s disease: Elevated pigment epithelium-derived factor in the cerebrospinal fluid is mostly of systemic origin. J Neurol Sci. 2017;375:123-128","DOI":"10.1016\/j.jns.2017.01.051"},{"key":"key-10.17116\/jnevro202512504243-60","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031731"},{"key":"key-10.17116\/jnevro202512504243-61","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316603"},{"key":"key-10.17116\/jnevro202512504243-62","unstructured":"Strain JF, Smith RX, Beaumont H, et al. Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions. Neurology. 2011; 56(7):23-29"},{"key":"key-10.17116\/jnevro202512504243-63","doi-asserted-by":"crossref","unstructured":"Wang J, Huang R, Tian S, et al. Elevated plasma level of D-dimer predicts the high risk of early cognitive impairment in type 2 diabetic patients as carotid artery plaques become vulnerable or get aggravated. Curr Alzheimer Res. 2019;16(5):396-404","DOI":"10.2174\/1567205016666190321164741"},{"key":"key-10.17116\/jnevro202512504243-64","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-201565"},{"key":"key-10.17116\/jnevro202512504243-65","doi-asserted-by":"publisher","DOI":"10.1111\/psyg.12403"},{"key":"key-10.17116\/jnevro202512504243-66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000322"},{"key":"key-10.17116\/jnevro202512504243-67","doi-asserted-by":"publisher","DOI":"10.18632\/aging.101924"},{"key":"key-10.17116\/jnevro202512504243-68","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-015-0233-3"},{"key":"key-10.17116\/jnevro202512504243-69","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00146.2017"},{"key":"key-10.17116\/jnevro202512504243-70","doi-asserted-by":"publisher","DOI":"10.1080\/00207454.2016.1193861"},{"key":"key-10.17116\/jnevro202512504243-71","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19807-y"},{"key":"key-10.17116\/jnevro202512504243-72","doi-asserted-by":"crossref","unstructured":"Brosseron F, Krauthausen M, Kummer M, Heneka MT. Body fluid cytokine levels in mild cognitive impairment and Alzheimer\u2019s disease: a comparative overview. Mol Neurobiol. 2014;50(2):534-544","DOI":"10.1007\/s12035-014-8657-1"}],"container-title":["S.S. Korsakov Journal of Neurology and Psychiatry"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T05:15:11Z","timestamp":1748322911000},"score":1,"resource":{"primary":{"URL":"https:\/\/mediasphera.ru\/issues\/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova-2\/2025\/4-2\/1199772982025042043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,5,27]]}},"alternative-id":["10.17116\/jnevro202512504243"],"URL":"https:\/\/doi.org\/10.17116\/jnevro202512504243","relation":{},"ISSN":["1997-7298"],"issn-type":[{"value":"1997-7298","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,27]]}}}